The publication of this article was supported by Bristol Myers Squibb.
The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a result of advancements in biomarker testing. However, unmet needs remain both in terms of treatment options for some patient groups, and patient support throughout the treatment journey. In this symposium, Jarushka Naidoo, Terri Conneran, Luis Paz-Ares and Alexander Drilon focused on patient-centric approaches to mNSCLC treatment.
The panel also discussed both I-O monotherapy and combination therapy, including dual I-O therapies for patients with PD-L1 tumour expression <1%, as well as the treatment landscape for KRAS (G12C – in superscript)-mutated mNSCLC. In addition, the latest data on TKIs for patients with alterations in ROS1 and NTRK genes were discussed, focusing on next‑generation TKIs.
Faculty
Jarushka Naidoo1
Terri Conneran2
Luis Paz-Ares3
Alexander Drilon4
1. Jarushka Naidoo,MBBCh, MHS (Chair) Beaumont RCSICancer Centre Dublin, Ireland
2. Terri Conneran KRAS Kickers Charlotte, North Carolina, United States
3. Luis Paz-Ares, MD, PhD Hospital Universitario12 de Octubre Madrid, Spain
4. Alexander Drilon, MD Memorial Sloan Kettering Cancer Center, New York, New York, United States
